What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer?
1 Kenju Ando, MD, and Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan; Kenichi Yoshimura, PhD, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Kasumi, Minami-ku, Hiroshima, Japan; and Yukino Kawamura, MD, and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.